1. A neurologist is initiating pramipexole in a patient with Parkinson's disease and renal impairment. Which of the following correctly describes the dose-adjustment principle that applies based on creatinine clearance (CrCl)?
A) Pramipexole requires no dose adjustment for any degree of renal impairment because it undergoes complete hepatic metabolism before reaching the systemic circulation
B) Pramipexole dose adjustment is optional and guided by symptom tolerance rather than by renal function, because plasma concentrations do not rise meaningfully as CrCl declines
C) Because pramipexole is eliminated almost entirely by renal excretion as unchanged drug, declining renal function mandates a lower starting dose, slower titration, and a reduced maximum daily dose, with the degree of reduction increasing as CrCl falls
D) Pramipexole should be avoided entirely in any patient with CrCl below 60 mL/min because accumulation at any level of renal impairment causes irreversible dopaminergic neurotoxicity
E) Pramipexole dose adjustment in renal impairment follows the same protocol as ropinirole — both require proportional reduction based on GFR because both are renally cleared
ANSWER: C
Rationale:
Pramipexole is eliminated almost entirely by renal excretion — with roughly 90% recovered in the urine as unchanged drug and less than 10% undergoing hepatic metabolism. Because its clearance falls in proportion to declining creatinine clearance, dose adjustment in renal impairment is mandatory rather than optional, and it is accomplished by lowering the starting dose, lengthening the titration interval, and capping the maximum daily dose according to the patient's CrCl. The degree of restriction increases as renal function worsens, so a patient with moderate impairment requires a more conservative regimen than a patient with normal renal function, and a patient with severe impairment requires greater restriction still. The prescriber should consult the current prescribing information for the specific CrCl thresholds and corresponding dose limits in effect. Option C is correct.
Option A: Option A is incorrect because pramipexole does not undergo complete hepatic metabolism; its oral bioavailability is approximately 90% precisely because first-pass hepatic metabolism is minimal, and its primary elimination route is renal.
Option B: Option B is incorrect because pramipexole dose adjustment in renal impairment is pharmacokinetically mandated, not optional; clearance is directly proportional to creatinine clearance, so plasma concentrations rise as CrCl declines, and a patient may accumulate drug to toxic levels while still appearing to tolerate the dose.
Option D: Option D is incorrect because pramipexole is not avoided entirely below CrCl 60 mL/min; it can be used with appropriate dose reduction, and there is no established irreversible neurotoxicity from drug accumulation in renal impairment.
Option E: Option E is incorrect because ropinirole does not require renal dose adjustment — it is cleared by hepatic CYP1A2 metabolism, not by renal excretion; the two agents have fundamentally different elimination pathways and different dose-adjustment requirements in renal impairment.
2. Which of the following correctly describes the oral bioavailability of ropinirole and the mechanism responsible for it?
A) Ropinirole has an oral bioavailability of approximately 50%, reduced from complete absorption by significant first-pass hepatic metabolism primarily via CYP1A2
B) Ropinirole has an oral bioavailability of approximately 90%, reflecting minimal first-pass metabolism and near-complete gastrointestinal absorption, similar to pramipexole
C) Ropinirole has an oral bioavailability of approximately 37%, limited by transdermal delivery through the skin barrier rather than gastrointestinal absorption
D) Ropinirole has an oral bioavailability of approximately 50%, reduced by P-glycoprotein efflux at the intestinal wall that pumps absorbed drug back into the gut lumen before it reaches the portal circulation
E) Ropinirole has an oral bioavailability of approximately 15%, reflecting extensive first-pass metabolism by both CYP1A2 and CYP3A4 in the gut wall and liver, making it the least bioavailable of the non-ergot agonists
ANSWER: A
Rationale:
Ropinirole's oral bioavailability is approximately 50%, reduced substantially from complete absorption by significant first-pass hepatic metabolism. The primary enzyme responsible is CYP1A2, which metabolizes ropinirole in the liver before it reaches the systemic circulation. This first-pass effect is clinically important because it creates the basis for drug interactions — CYP1A2 inhibitors such as fluvoxamine can increase ropinirole plasma concentrations by up to 80% by reducing this first-pass clearance, and CYP1A2 inducers such as cigarette smoke reduce systemic exposure. Option A is correct.
Option B: Option B is incorrect because 90% bioavailability describes pramipexole, not ropinirole; pramipexole undergoes minimal hepatic first-pass metabolism, achieving high bioavailability, whereas ropinirole's CYP1A2-mediated first-pass metabolism substantially reduces its systemic availability.
Option C: Option C is incorrect because 37% bioavailability describes rotigotine's transdermal delivery through the skin barrier; ropinirole is an oral agent, not a transdermal formulation.
Option D: Option D is incorrect because P-glycoprotein efflux is not the primary mechanism limiting ropinirole bioavailability; the reduction in systemic availability is due to hepatic CYP1A2-mediated first-pass metabolism, not intestinal efflux transport.
Option E: Option E is incorrect because ropinirole bioavailability is approximately 50%, not 15%; CYP3A4 plays only a minor role in ropinirole metabolism relative to CYP1A2, and 15% would represent a degree of first-pass extraction far greater than what is pharmacokinetically established for this drug.
3. Which of the following correctly distinguishes the receptor profile of rotigotine from that of pramipexole and ropinirole?
A) Rotigotine is selective for D2 receptors only, whereas pramipexole and ropinirole act at both D2 and D3 receptors, giving the non-patch agents a broader receptor profile
B) Rotigotine has greater D3 receptor affinity than either pramipexole or ropinirole, making it the agent most associated with impulse control disorders among the non-ergot agonists
C) Rotigotine acts exclusively at D1 receptors, explaining why it produces a more complete motor response than pramipexole or ropinirole at equivalent doses
D) Pramipexole, ropinirole, and rotigotine all share identical receptor profiles — D2 and D3 preferential — and differ only in their routes of administration and pharmacokinetic parameters
E) Rotigotine has a broader receptor profile than pramipexole or ropinirole, acting at D1, D2, D3, and D4 receptors as well as partial agonism at 5-HT1A receptors, whereas pramipexole and ropinirole act primarily at D2-family receptors without meaningful D1 activity
ANSWER: E
Rationale:
Rotigotine is pharmacologically distinguished from pramipexole and ropinirole by its broader receptor profile. It acts as an agonist at D1, D2, D3, and D4 receptors, and also shows partial agonism at 5-HT1A receptors; it does not activate 5-HT2B receptors at therapeutic concentrations. Pramipexole and ropinirole, by contrast, act primarily at D2-family receptors (D2, D3, D4) and do not meaningfully stimulate D1 receptors at therapeutic concentrations. This makes rotigotine the only transdermal non-ergot agonist with D1 receptor activity, though the clinical motor benefit of this broader receptor profile relative to pure D2-family agonists has not been definitively established. Option E is correct.
Option A: Option A is incorrect because the receptor profile comparison is inverted — rotigotine has the broader profile, not the narrower one; pramipexole and ropinirole act at D2 and D3 receptors, but rotigotine adds D1 and 5-HT1A activity.
Option B: Option B is incorrect because rotigotine does not have greater D3 affinity than pramipexole; pramipexole has the highest relative D3 affinity among the non-ergot oral agonists, and the D3-mediated impulse control disorder risk is primarily associated with pramipexole and ropinirole.
Option C: Option C is incorrect because rotigotine is not selective for D1 receptors — D1 activity is part of its broader profile, not its defining characteristic; and the claim that it produces more complete motor responses than pramipexole or ropinirole at equivalent doses is not an established clinical finding.
Option D: Option D is incorrect because the three non-ergot agonists do not share identical receptor profiles; rotigotine's D1 activity and 5-HT1A partial agonism are meaningfully distinct from the D2-family-predominant profiles of pramipexole and ropinirole.
4. Which of the following correctly states the plasma half-life of subcutaneous apomorphine and explains why oral administration is not a viable route for this drug?
A) Apomorphine has a plasma half-life of approximately 6 hours after subcutaneous injection and cannot be given orally because it is degraded by gastric acid before reaching the small intestine
B) Apomorphine has a plasma half-life of approximately 40 minutes after subcutaneous injection and cannot be given orally because it undergoes extensive and rapid first-pass hepatic metabolism that renders oral bioavailability negligible
C) Apomorphine has a plasma half-life of approximately 40 minutes after subcutaneous injection and cannot be given orally because it is a substrate for intestinal P-glycoprotein efflux that completely prevents gastrointestinal absorption
D) Apomorphine has a plasma half-life of approximately 4 hours after subcutaneous injection and is not given orally as a matter of clinical convention rather than pharmacokinetic necessity, since oral bioavailability is approximately 30%
E) Apomorphine has a plasma half-life of approximately 40 minutes after subcutaneous injection and cannot be given orally because it forms an insoluble complex with gastrointestinal mucins, preventing mucosal absorption
ANSWER: B
Rationale:
The plasma half-life of apomorphine after subcutaneous injection is approximately 40 minutes, consistent with its brief duration of motor benefit (45 to 90 minutes per dose) and its clinical utility as an acute rescue agent rather than a maintenance therapy. Oral administration is not viable because apomorphine undergoes extensive and rapid first-pass hepatic metabolism that renders oral bioavailability negligible — the drug is almost completely extracted by the liver on first pass, leaving insufficient systemic concentrations to produce a therapeutic effect. This is why apomorphine is administered parenterally: subcutaneously for rescue injection and via continuous subcutaneous infusion for advanced disease management. Option B is correct.
Option A: Option A is incorrect because apomorphine's half-life is approximately 40 minutes, not 6 hours; a 6-hour half-life would be inconsistent with its brief duration of action and its use as a rescue agent. The mechanism stated — gastric acid degradation — is also incorrect; first-pass hepatic metabolism is the primary barrier to oral use.
Option C: Option C is incorrect because while P-glycoprotein efflux exists at the intestinal wall, it is not the mechanism that prevents oral apomorphine use; the dominant barrier is hepatic first-pass metabolism, not intestinal efflux transport.
Option D: Option D is incorrect because the half-life is approximately 40 minutes, not 4 hours, and oral bioavailability is not approximately 30% — it is negligible due to extensive first-pass metabolism; the inability to use oral apomorphine is pharmacokinetically determined, not a convention.
Option E: Option E is incorrect because mucin complex formation is not a recognized mechanism limiting apomorphine absorption; the correct explanation is first-pass hepatic metabolism.
5. A patient with Parkinson's disease on levodopa develops gastroparesis with significant nausea and vomiting. A colleague suggests metoclopramide for symptom control. Which of the following best explains why metoclopramide is contraindicated in this patient?
A) Metoclopramide is a potent CYP1A2 inhibitor that substantially increases levodopa plasma concentrations, raising the risk of levodopa toxicity and dyskinesias
B) Metoclopramide irreversibly inhibits aromatic amino acid decarboxylase in the gut wall, preventing peripheral conversion of levodopa and reducing its systemic availability
C) Metoclopramide activates peripheral 5-HT3 receptors in the gastric wall, producing paradoxical worsening of gastroparesis through a serotonergic mechanism
D) Metoclopramide crosses the blood-brain barrier and blocks central dopamine D2 receptors in the striatum, directly antagonizing the dopaminergic activity that antiparkinsonian therapy depends on and worsening motor function
E) Metoclopramide chelates levodopa in the gastrointestinal tract, forming an insoluble complex that prevents levodopa absorption and precipitates acute motor deterioration
ANSWER: D
Rationale:
Metoclopramide is a dopamine D2 receptor antagonist with significant central nervous system penetration. In Parkinson's disease, antiparkinsonian therapy — whether levodopa or a dopamine agonist — depends on dopaminergic activity at striatal D2 receptors. Metoclopramide crosses the blood-brain barrier and blocks these central D2 receptors, directly opposing the mechanism of action of antiparkinsonian treatment and causing acute worsening of motor function. This makes metoclopramide specifically contraindicated in all patients with Parkinson's disease. Domperidone — a peripherally acting D2 antagonist that does not cross the blood-brain barrier — is the appropriate alternative for gastroparesis or nausea management in PD patients. Option D is correct.
Option A: Option A is incorrect because metoclopramide is not a clinically significant CYP1A2 inhibitor and does not substantially affect levodopa plasma concentrations through enzyme inhibition; its harm in PD is through central D2 receptor blockade, not a pharmacokinetic interaction with levodopa.
Option B: Option B is incorrect because metoclopramide does not inhibit aromatic amino acid decarboxylase; decarboxylase inhibition in the periphery is the mechanism of carbidopa, which is co-administered with levodopa therapeutically to increase central availability.
Option C: Option C is incorrect because metoclopramide's prokinetic effect is mediated partly through 5-HT4 receptor agonism and D2 antagonism in the gut; 5-HT3 activation in the gastric wall is not its mechanism and would not explain its contraindication in PD.
Option E: Option E is incorrect because chelation of levodopa in the gastrointestinal tract is not a recognized interaction between metoclopramide and levodopa; the contraindication is pharmacodynamic — central D2 receptor blockade — not pharmacokinetic.
6. The pivotal randomized trial comparing ropinirole versus levodopa as initial therapy in early Parkinson's disease demonstrated a significant difference in dyskinesia incidence at 5 years. Which of the following correctly states those incidence figures and identifies the most important clinical qualification of the result?
A) Ropinirole produced dyskinesia in approximately 45% of patients versus approximately 20% with levodopa at 5 years, confirming that ropinirole carries a higher dyskinesia risk than levodopa when used as initial therapy
B) Both ropinirole and levodopa produced dyskinesia in fewer than 5% of patients at 5 years; the trial's main finding was that motor fluctuations, not dyskinesias, were the primary distinguishing complication
C) Ropinirole produced dyskinesia in approximately 20% of patients versus approximately 45% with levodopa at 5 years; the critical qualification is that the majority of ropinirole-treated patients required supplemental levodopa within 2 to 3 years, and the lower dyskinesia rate reflects at least in part reduced cumulative levodopa exposure rather than a durable protective effect of ropinirole itself
D) Ropinirole produced dyskinesia in approximately 20% of patients versus approximately 45% with levodopa at 5 years, and this benefit was sustained at 10 years with the same absolute difference, confirming that agonist-first therapy permanently prevents levodopa-induced dyskinesias
E) Ropinirole produced dyskinesia in approximately 10% of patients versus approximately 31% with levodopa at 5 years — figures that represent the pramipexole trial results, not the ropinirole trial; the ropinirole trial showed no significant difference between treatment arms
ANSWER: C
Rationale:
The pivotal ropinirole versus levodopa trial (056 Study Group) demonstrated dyskinesia incidence of approximately 20% in the ropinirole arm versus approximately 45% in the levodopa arm at 5 years — a clinically meaningful difference that established the rationale for agonist-first therapy in younger patients. However, the critical qualification of this result is that the majority of ropinirole-treated patients required supplemental levodopa within 2 to 3 years because agonist monotherapy alone was insufficient for sustained motor control as disease progressed. The lower dyskinesia rate in the ropinirole group therefore reflects at least in part a lower cumulative levodopa exposure in those patients, rather than a specific and durable neuroprotective or receptor-sensitization-preventing effect of ropinirole itself. The agonist-first strategy delays dyskinesia onset but does not eliminate or permanently prevent it. Option C is correct.
Option A: Option A is incorrect because the figures are reversed; ropinirole had the lower dyskinesia rate (approximately 20%) and levodopa had the higher rate (approximately 45%), not the other way around.
Option B: Option B is incorrect because dyskinesia rates were not below 5% in either arm at 5 years; the approximately 45% rate in the levodopa group reflects the well-established dyskinesia burden of long-term levodopa therapy in moderate-to-advanced PD.
Option D: Option D is incorrect because the dyskinesia advantage of agonist-first therapy was not shown to be sustained at 10 years with the same absolute difference, and the claim that agonist-first permanently prevents levodopa-induced dyskinesias contradicts the established evidence — most patients eventually require levodopa and eventually develop dyskinesias.
Option E: Option E is incorrect because the figures approximately 10% versus approximately 31% describe the pramipexole versus levodopa trial (Parkinson Study Group), not the ropinirole trial; and the ropinirole trial did demonstrate a statistically significant difference between treatment arms.
7. The Parkinson Study Group trial comparing pramipexole versus levodopa as initial therapy reported dyskinesia incidence figures at 4 to 5 years that differed from those of the ropinirole trial. Which of the following correctly states the pramipexole trial's dyskinesia findings and the shared mechanistic explanation for the lower dyskinesia rate in the agonist arm across both trials?
A) The pramipexole trial showed approximately 10% dyskinesia incidence with initial pramipexole versus approximately 31% with initial levodopa at 4 to 5 years; as in the ropinirole trial, the lower dyskinesia rate in the agonist arm reflects at least in part lower cumulative levodopa exposure, since most agonist-treated patients required supplemental levodopa within 2 to 3 years
B) The pramipexole trial showed approximately 20% dyskinesia with pramipexole versus approximately 45% with levodopa — figures identical to the ropinirole trial — confirming that both agonists confer equivalent dyskinesia protection regardless of their individual receptor profiles
C) The pramipexole trial showed approximately 10% dyskinesia with pramipexole versus approximately 31% with levodopa, and this lower rate was conclusively proven to result from pramipexole's direct neuroprotective effect on surviving dopaminergic neurons rather than from differences in levodopa exposure
D) The pramipexole trial showed approximately 31% dyskinesia with pramipexole versus approximately 10% with levodopa — demonstrating that pramipexole's high D3 affinity accelerates striatal sensitization and increases dyskinesia risk relative to levodopa
E) The pramipexole trial showed no significant difference in dyskinesia rates between arms at 5 years; the apparent benefit in the ropinirole trial was attributed to ropinirole's unique receptor profile and was not reproduced with pramipexole
ANSWER: A
Rationale:
The Parkinson Study Group trial demonstrated dyskinesia incidence of approximately 10% in the initial pramipexole arm versus approximately 31% in the initial levodopa arm at 4 to 5 years. This approximately 21 percentage point difference is smaller in absolute terms than the approximately 25 percentage point difference observed in the ropinirole trial (approximately 20% versus approximately 45%), but both trials consistently demonstrated the same direction of effect: initial agonist therapy was associated with substantially lower dyskinesia rates than initial levodopa. The shared mechanistic explanation across both trials is that most agonist-treated patients required supplemental levodopa within 2 to 3 years, and the lower cumulative levodopa dose in patients who began on agonists contributed meaningfully to the lower dyskinesia incidence — the agonist-first strategy reduces early levodopa exposure, delaying the pulsatile receptor stimulation that drives dyskinesia development. Option A is correct.
Option B: Option B is incorrect because the pramipexole trial figures (approximately 10% versus approximately 31%) are not identical to the ropinirole trial figures (approximately 20% versus approximately 45%); both trials show a consistent advantage for agonist-first, but the absolute rates differ, reflecting differences in study populations, trial design, and the agents themselves.
Option C: Option C is incorrect because neuroprotection has not been conclusively proven for pramipexole or any dopamine agonist; the lower dyskinesia rate in the agonist arm is most parsimoniously explained by lower cumulative levodopa exposure, not by a direct neuroprotective mechanism.
Option D: Option D is incorrect because the figures are reversed; pramipexole had the lower dyskinesia rate (approximately 10%), not the higher one; and high D3 affinity is associated with impulse control disorders, not with accelerated striatal sensitization or increased dyskinesia risk.
Option E: Option E is incorrect because both the pramipexole and ropinirole trials demonstrated statistically significant differences in dyskinesia rates favoring the agonist arm; the pramipexole trial did not fail to reproduce the ropinirole trial finding.
8. Pergolide was withdrawn from the US market in 2007 due to fibrotic valvulopathy. Cabergoline, also an ergot agonist with the same 5-HT2B receptor mechanism, remains available. Which of the following correctly describes the current clinical status of cabergoline in Parkinson's disease and the monitoring requirement for patients who continue to take it?
A) Cabergoline was withdrawn from all markets simultaneously with pergolide in 2007 and is no longer available for any indication in the United States or Europe
B) Cabergoline is approved as first-line therapy for newly diagnosed Parkinson's disease in patients over 70 years because its once-weekly dosing improves adherence and its valvulopathy risk is negligible at low doses
C) Cabergoline is freely available for Parkinson's disease without restriction because subsequent studies demonstrated that its 5-HT2B receptor activity does not produce clinically significant valvular changes at doses used for PD
D) Cabergoline carries no monitoring requirement because echocardiographic abnormalities attributed to it in earlier studies were subsequently shown to be caused by the underlying Parkinson's disease process rather than the drug
E) Cabergoline remains available but is restricted for use in Parkinson's disease in most guidelines; patients who cannot be switched to a non-ergot agonist require periodic echocardiographic surveillance to detect valvular regurgitation, as the risk of fibrotic valvulopathy is dose-dependent and cumulative
ANSWER: E
Rationale:
Unlike pergolide, which was withdrawn from the US market in 2007, cabergoline was not formally withdrawn but has been restricted for Parkinson's disease use in most clinical guidelines because it shares the same 5-HT2B receptor mechanism responsible for fibrotic valvulopathy. Cabergoline remains available for other indications, including hyperprolactinemia, where lower doses reduce but do not eliminate the risk. For patients with Parkinson's disease who are already on cabergoline and cannot be safely transitioned to a non-ergot agent, periodic echocardiographic surveillance is required to detect early valvular changes, since the valvulopathy risk is both dose-dependent and cumulative. Initiation of cabergoline as new treatment for PD is not recommended given the availability of non-ergot alternatives. Option E is correct.
Option A: Option A is incorrect because cabergoline was not withdrawn from all markets simultaneously with pergolide; pergolide was voluntarily withdrawn from the US market in 2007, while cabergoline remains available with restrictions.
Option B: Option B is incorrect because cabergoline is not approved as first-line PD therapy; it is specifically restricted in PD guidelines precisely because of its valvulopathy risk, and the risk is not negligible at doses used for PD.
Option C: Option C is incorrect because subsequent studies did not exonerate cabergoline — they confirmed the 5-HT2B-mediated valvulopathy risk and led to its restriction, not its liberation from guidelines.
Option D: Option D is incorrect because the echocardiographic abnormalities associated with ergot agonists were not attributed to Parkinson's disease itself; they are drug-induced, dose-dependent, and mechanistically identical to the valvulopathy produced by other 5-HT2B agonists such as fenfluramine, establishing causality for the ergot agents.
9. Impulse control disorders (ICDs) in Parkinson's disease patients on dopamine agonists frequently go undetected because patients do not volunteer the behaviors. Which of the following correctly identifies the validated screening instrument designed specifically to detect ICDs in PD patients, and names the behaviors it screens for?
A) The Montreal Cognitive Assessment (MoCA) is the validated tool for detecting ICDs in PD; it screens for gambling, hypersexuality, compulsive eating, and repetitive motor behaviors as part of its executive function domain
B) The QUIP (Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease) is the validated screening tool for ICDs in PD; it specifically screens for pathological gambling, hypersexuality, compulsive buying, compulsive eating, and other repetitive behaviors such as punding
C) The UPDRS (Unified Parkinson's Disease Rating Scale) Part II includes a dedicated ICD subscale that quantifies gambling, hypersexuality, and compulsive spending behaviors as non-motor complications of dopaminergic therapy
D) The PHQ-9 (Patient Health Questionnaire-9) has been validated as the primary ICD screening tool in PD because impulsivity and reward-seeking behavior overlap substantially with depressive symptoms, making a unified instrument more efficient
E) No validated screening tool exists specifically for ICDs in PD; clinical guidelines recommend unstructured clinical interview at each visit rather than a standardized questionnaire, as structured tools have not demonstrated adequate sensitivity in PD populations
ANSWER: B
Rationale:
The QUIP — Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease — is the validated, disease-specific screening instrument for impulse control disorders in PD patients on dopaminergic therapy. It screens for the full spectrum of ICD behaviors recognized in PD: pathological gambling, hypersexuality, compulsive buying, compulsive eating, and repetitive/compulsive behaviors such as punding (stereotyped, purposeless motor activities). Because ICD behaviors are frequently not volunteered by patients due to shame or lack of awareness that their behaviors are medication-related, structured screening with the QUIP at each clinic visit is recommended for all patients on dopamine agonist therapy. Option B is correct.
Option A: Option A is incorrect because the Montreal Cognitive Assessment (MoCA) is a cognitive screening instrument, not an ICD screening tool; it assesses memory, attention, visuospatial function, language, and executive function but does not screen for impulsive-compulsive behaviors associated with dopaminergic therapy.
Option C: Option C is incorrect because the UPDRS (Unified Parkinson's Disease Rating Scale) does not include a validated ICD subscale; it is a motor and non-motor symptom severity rating scale primarily assessing motor function, activities of daily living, and treatment complications such as dyskinesias and fluctuations, but not ICD behaviors specifically.
Option D: Option D is incorrect because the PHQ-9 is a depression screening questionnaire and has not been validated as an ICD screening tool in PD; while depression and impulsivity have some neurobiological overlap, they are distinct phenomena requiring dedicated assessment instruments.
Option E: Option E is incorrect because the QUIP is a validated, disease-specific instrument with established sensitivity and specificity for ICD detection in PD; clinical guidelines do recommend structured screening, not only unstructured interview.
10. Which of the following correctly identifies the patient characteristics associated with increased risk of dopamine dysregulation syndrome (DDS) in Parkinson's disease?
A) DDS is most common in patients over 75 years with late-onset PD, female sex, no prior psychiatric history, and high educational attainment — a risk profile distinct from that of impulse control disorders
B) DDS risk is determined exclusively by the total daily levodopa equivalent dose; patient demographic and psychiatric characteristics have not been shown to predict DDS independent of dose
C) DDS is associated with older age at PD onset, female sex, and concurrent use of both levodopa and a dopamine agonist; it does not occur in patients on levodopa monotherapy
D) DDS is associated with young-onset Parkinson's disease, male sex, a personal history of substance misuse or alcohol dependence, impulsive personality traits, and depression — a profile that overlaps substantially with risk factors for impulse control disorders, and DDS and ICD frequently co-exist in the same patient
E) DDS is associated exclusively with dopamine agonist use and does not occur with levodopa; the compulsive overuse seen in DDS is driven specifically by D3 receptor activation in the mesolimbic system and is absent when D3-selective agents are not prescribed
ANSWER: D
Rationale:
Dopamine dysregulation syndrome is a compulsive overuse of dopaminergic medications — most commonly levodopa but also dopamine agonists — driven by the hedonic and stimulant-like effects of high-dose dopaminergic activity in the mesolimbic system. The risk profile for DDS is well characterized and includes: young onset of Parkinson's disease (patients with decades of disease course ahead have greater cumulative exposure to dopaminergic therapy and its rewarding effects), male sex, a personal history of substance misuse or alcohol dependence (reflecting underlying reward pathway vulnerability), impulsive personality traits, and depression. This risk profile overlaps substantially with that of impulse control disorders, and DDS and ICD frequently co-exist in the same patient — the two conditions share mesolimbic dopaminergic pathophysiology but differ in that DDS targets the medications themselves while ICD targets external reward activities. Option D is correct.
Option A: Option A is incorrect because DDS risk is associated with young-onset PD and male sex, not older age and female sex; the stated risk profile in option A is the approximate inverse of the established one.
Option B: Option B is incorrect because patient characteristics — particularly young onset, male sex, and prior substance history — independently predict DDS risk beyond dose alone; dose is a contributing factor but not the sole determinant.
Option C: Option C is incorrect because DDS is not restricted to patients on combined levodopa and agonist therapy; it most commonly manifests as compulsive overuse of levodopa itself, and it can occur with levodopa monotherapy.
Option E: Option E is incorrect because DDS most commonly involves levodopa, not exclusively dopamine agonists; while D3 receptor activation contributes to the mesolimbic reward sensitization underlying DDS, the syndrome is defined by compulsive medication overuse regardless of which dopaminergic agent is misused.
11. Continuous subcutaneous apomorphine infusion (CSAI) is used in advanced Parkinson's disease with refractory motor complications. Which of the following correctly states the efficacy outcomes and the principal adverse effect that limits long-term use?
A) CSAI reduces off time by approximately 10 to 20% and allows levodopa dose reduction of approximately 5 to 10%; the principal limiting adverse effect is QTc prolongation, which requires withdrawal in the majority of patients within the first year
B) CSAI reduces off time by approximately 50 to 70% and allows levodopa equivalent dose reduction of approximately 30 to 50%; the principal limiting adverse effect of long-term CSAI is hemolytic anemia due to a Coombs-positive immune reaction, which occurs in the majority of patients within 12 months and necessitates discontinuation
C) CSAI reduces off time by approximately 50 to 70% and allows levodopa equivalent dose reduction of approximately 30 to 50%; the principal limiting adverse effect of long-term CSAI is skin nodules and subcutaneous indurations at injection sites, which develop in most patients with prolonged use and can eventually restrict viable injection areas
D) CSAI reduces off time by approximately 50 to 70%; however, it does not allow levodopa dose reduction because apomorphine and levodopa act at non-overlapping receptor populations and their motor benefits are purely additive without permitting dose reduction of either agent
E) CSAI reduces off time by approximately 20 to 30% and allows levodopa dose reduction of approximately 50 to 60%; the principal limiting adverse effect is application site reactions including erythema and contact dermatitis, which are managed by rotating the infusion site daily
ANSWER: C
Rationale:
Continuous subcutaneous apomorphine infusion delivers apomorphine via a programmable pump over 12 to 16 waking hours, providing continuous dopaminergic stimulation that substantially reduces both off time and the required levodopa dose in patients with advanced PD and refractory motor complications. Observational studies and prospective series have consistently reported reductions in off time of 50 to 70% and reductions in levodopa equivalent dose of 30 to 50% in patients successfully established on CSAI. The principal limiting adverse effect of long-term CSAI is the development of skin nodules and subcutaneous indurations at infusion sites, which occur in most patients with prolonged use. These nodules develop progressively with cumulative injection site exposure and can eventually restrict the number of viable sites for infusion placement, limiting continued CSAI use. Management includes systematic site rotation, ultrasound-guided site selection, and in refractory cases transition to levodopa-carbidopa intestinal gel. Option C is correct.
Option A: Option A is incorrect because the efficacy figures of 10 to 20% off-time reduction and 5 to 10% levodopa dose reduction substantially understate the established clinical benefit of CSAI; and QTc prolongation is not the principal long-term adverse effect limiting CSAI — it is a concern during bolus apomorphine initiation, not continuous infusion.
Option B: Option B is incorrect because while Coombs-positive hemolytic anemia is a recognized rare complication of long-term CSAI, it does not occur in the majority of patients and is not the principal limiting adverse effect; the correct answer identifies skin nodules and subcutaneous indurations as the dominant long-term limiting complication.
Option D: Option D is incorrect because CSAI does permit meaningful levodopa dose reduction of 30 to 50%; apomorphine's broad D1 and D2 receptor agonism provides sufficient dopaminergic coverage to allow reduction of concurrent oral levodopa, and this dose-sparing effect is one of the established clinical advantages of CSAI.
Option E: Option E is incorrect because the off-time reduction figure of 20 to 30% understates the established efficacy of CSAI; application site reactions such as erythema and contact dermatitis are more characteristic of the rotigotine transdermal patch, not of subcutaneous apomorphine infusion, whose principal long-term site complication is nodule and induration formation rather than inflammatory skin reactions.
12. Which of the following correctly describes the bioavailability, elimination pathway, and renal dose-adjustment requirement for rotigotine transdermal patch?
A) Rotigotine delivered via transdermal patch has a bioavailability of approximately 37% of the total patch content, reflecting the skin as an absorptive barrier; it undergoes extensive hepatic metabolism with excretion of metabolites in urine and feces; and no meaningful renal dose adjustment is required
B) Rotigotine has a transdermal bioavailability of approximately 90%, comparable to the oral bioavailability of pramipexole, because the patch bypasses first-pass metabolism entirely; it is eliminated unchanged by renal excretion and requires dose reduction for CrCl below 50 mL/min
C) Rotigotine has a transdermal bioavailability of approximately 37%, is eliminated unchanged by renal tubular secretion as unchanged drug, and requires the same mandatory dose-reduction schedule as pramipexole in renal impairment
D) Rotigotine has a transdermal bioavailability of approximately 15% due to CYP3A4-mediated metabolism in the skin itself before systemic absorption; it is hepatically cleared and requires no renal adjustment but does require dose reduction for severe hepatic impairment
E) Rotigotine has a transdermal bioavailability of approximately 37% and is eliminated primarily by CYP1A2 hepatic metabolism; smoking cessation therefore increases rotigotine plasma concentrations by the same mechanism as it does for ropinirole, requiring dose reduction in patients who quit smoking
ANSWER: A
Rationale:
Rotigotine transdermal patch achieves a bioavailability of approximately 37% of the total drug content in the patch, with the skin barrier acting as the rate-limiting absorptive interface. The patch delivers drug at a constant rate through the skin, bypassing gastrointestinal absorption and first-pass hepatic metabolism; however, not all drug in the patch is absorbed, giving a fractional transdermal bioavailability of approximately 37%. Once in the systemic circulation, rotigotine undergoes extensive hepatic metabolism through CYP-mediated conjugation reactions, with metabolites excreted in both urine and feces. Because renal excretion of unchanged rotigotine is not a significant elimination pathway, no meaningful dose adjustment is required for renal impairment. Option A is correct.
Option B: Option B is incorrect because rotigotine's transdermal bioavailability is approximately 37%, not 90%; bypassing first-pass metabolism does not guarantee high bioavailability because the skin itself is an absorptive barrier with limited permeability. Additionally, rotigotine is not eliminated unchanged by renal excretion and does not require the renal dose-adjustment schedule described.
Option C: Option C is incorrect because rotigotine is not eliminated by renal tubular secretion as unchanged drug — that is pramipexole's elimination route; rotigotine undergoes hepatic metabolism and does not require the renal dose-adjustment schedule that pramipexole requires.
Option D: Option D is incorrect because CYP3A4-mediated metabolism in the skin itself is not the established mechanism limiting rotigotine transdermal bioavailability; the skin acts as a physical absorption barrier, not primarily as a site of enzymatic degradation.
Option E: Option E is incorrect because rotigotine is not primarily metabolized by CYP1A2; CYP1A2 is the principal enzyme for ropinirole metabolism, not rotigotine. The smoking cessation interaction with rising drug concentrations is specific to ropinirole and does not apply to rotigotine by the same mechanism.
13. A patient stable on ropinirole quits smoking. Over the following 3 weeks, ropinirole plasma concentrations rise and toxicity symptoms emerge without any dose change. Which of the following correctly identifies the mechanism and the required clinical response?
A) Smoking cessation reduces gastric motility, slowing ropinirole absorption and paradoxically increasing peak concentrations by prolonging the absorption phase; the clinical response is to take ropinirole with food to normalize absorption kinetics
B) Nicotine directly inhibits CYP1A2 during active smoking; when smoking ceases, CYP1A2 activity rebounds above normal baseline for 2 to 4 weeks before normalizing, transiently increasing ropinirole metabolism and lowering rather than raising plasma concentrations
C) Smoking cessation activates renal tubular secretion of ropinirole by removing nicotine's inhibitory effect on organic cation transporters, reducing renal clearance and causing drug accumulation
D) Nicotine withdrawal increases dopamine D2 receptor density in the striatum, pharmacodynamically sensitizing the patient to ropinirole's effects at the same plasma concentration, requiring dose reduction even without a change in drug levels
E) Cigarette smoke contains polycyclic aromatic hydrocarbons that induce CYP1A2; during active smoking, this induction accelerates ropinirole metabolism and maintains lower plasma concentrations; when smoking ceases, CYP1A2 induction reverses over 1 to 4 weeks, ropinirole metabolism slows, plasma concentrations rise at the unchanged dose, and ropinirole toxicity emerges — requiring proactive dose reduction
ANSWER: E
Rationale:
Cigarette smoke contains polycyclic aromatic hydrocarbons — not nicotine itself — that are potent inducers of CYP1A2, the hepatic enzyme primarily responsible for ropinirole metabolism. During active smoking, this CYP1A2 induction increases the rate of ropinirole clearance, maintaining plasma concentrations lower than they would be in a non-smoker at the same dose. When a patient on ropinirole quits smoking, the CYP1A2 induction gradually reverses over approximately 1 to 4 weeks as the inducing polycyclic aromatic hydrocarbons are cleared. As enzyme activity returns toward baseline, ropinirole metabolism slows, and plasma concentrations rise substantially at the same dose — producing toxicity symptoms despite no dose change. The correct clinical response is proactive dose reduction when a patient on ropinirole quits smoking, anticipating this pharmacokinetic change rather than waiting for toxicity to emerge. Option E is correct.
Option A: Option A is incorrect because the mechanism is not related to gastric motility or absorption kinetics; it is a hepatic CYP1A2 induction-de-induction effect on drug metabolism, and food does not correct the interaction.
Option B: Option B is incorrect because CYP1A2 induction is caused by polycyclic aromatic hydrocarbons in smoke, not by nicotine; when smoking ceases, CYP1A2 activity returns toward normal baseline rather than rebounding above it, resulting in reduced metabolism and higher drug levels, not lower.
Option C: Option C is incorrect because ropinirole is not significantly eliminated by renal tubular secretion — it is hepatically cleared via CYP1A2; organic cation transporter inhibition by nicotine is not the mechanism of this interaction.
Option D: Option D is incorrect because the primary mechanism of rising ropinirole toxicity after smoking cessation is pharmacokinetic — rising plasma drug concentrations due to reduced CYP1A2-mediated clearance — not pharmacodynamic upregulation of D2 receptor density.
14. A patient with Parkinson's disease is stable on pramipexole immediate-release (IR) 1 mg three times daily. His neurologist considers switching to pramipexole extended-release (ER) for convenience. Which of the following correctly describes the conversion and the pharmacokinetic difference between the two formulations?
A) Converting from pramipexole IR to ER requires a 20% dose increase because the extended-release formulation has lower bioavailability than the immediate-release tablet due to slower gastrointestinal absorption
B) Converting from pramipexole IR to ER uses the same total daily dose administered once daily; pramipexole ER produces a flatter plasma concentration profile than IR, reducing peak-related adverse effects while maintaining equivalent efficacy — in this patient, 3 mg once daily replaces 1 mg three times daily
C) Converting from pramipexole IR to ER requires halving the total daily dose because the extended-release formulation achieves higher peak plasma concentrations than IR due to slower elimination from a depot in the gastrointestinal wall
D) Pramipexole IR and ER are not interchangeable; they bind to different receptor subtypes at therapeutic concentrations, and a patient stable on IR must be re-titrated from the lowest ER dose rather than converting directly at the equivalent total daily dose
E) Converting from pramipexole IR to ER uses the same total daily dose; however, ER produces higher peak plasma concentrations than IR because absorption from the extended-release matrix is more complete, and patients must be monitored for increased adverse effects after conversion
ANSWER: B
Rationale:
The conversion from pramipexole immediate-release to extended-release is straightforward: the total daily dose is maintained and administered once daily rather than in divided doses. In this patient, 1 mg three times daily (total daily dose 3 mg) converts to pramipexole ER 3 mg once daily. Pramipexole ER achieves the same total drug exposure as IR over 24 hours but produces a flatter, more sustained plasma concentration profile — higher troughs and lower peaks compared with the three-times-daily IR regimen. This smoother plasma profile reduces peak-concentration-related adverse effects such as nausea and dizziness while maintaining equivalent antiparkinsonian efficacy, as demonstrated in randomized non-inferiority trials. Option B is correct.
Option A: Option A is incorrect because no dose increase is required when converting from IR to ER pramipexole; bioavailability is equivalent between formulations, and the total daily dose is maintained — not increased.
Option C: Option C is incorrect because dose halving is not required on conversion; the total daily dose is preserved, and pramipexole ER produces lower peak concentrations than IR — not higher — due to the extended-release delivery profile.
Option D: Option D is incorrect because pramipexole IR and ER contain the same active drug binding to the same receptor subtypes; the difference is the release rate, not the pharmacodynamic target; direct dose conversion without re-titration is the established standard.
Option E: Option E is incorrect because pramipexole ER produces lower peak plasma concentrations than IR, not higher; the extended-release matrix slows absorption and blunts peaks, and monitoring for increased adverse effects is not a specific requirement after straightforward conversion at the same total daily dose.
15. When a dopamine agonist is added as adjunctive therapy to levodopa in a patient with Parkinson's disease experiencing wearing-off motor fluctuations, what are the established efficacy outcomes in terms of off-time reduction and levodopa dose change?
A) Adding a dopamine agonist reduces off time by approximately 3 to 4 hours per day and requires levodopa dose increase of 20 to 40% to maintain adequate motor control during the transition period
B) Adding a dopamine agonist eliminates off time entirely in approximately 60% of patients and allows complete levodopa withdrawal in approximately 30% of patients who respond optimally
C) Adding a dopamine agonist reduces off time by approximately 30 minutes per day with no meaningful effect on levodopa dose requirements, making it a second-line option used only when COMT inhibitors and MAO-B inhibitors have both failed
D) Adding a dopamine agonist as adjunct to levodopa in patients with motor fluctuations consistently reduces off time by approximately 1 to 2 hours per day and allows levodopa dose reduction of approximately 10 to 30% without proportionately worsening motor control in patients who tolerate the addition
E) Adding a dopamine agonist reduces off time by approximately 1 to 2 hours per day but requires levodopa dose increase rather than reduction, because dopamine agonists and levodopa compete for the same striatal receptor population and partial agonist activity at D2 receptors reduces levodopa's intrinsic efficacy
ANSWER: D
Rationale:
When a dopamine agonist is added to levodopa therapy in patients with motor fluctuations, the consistently observed clinical outcomes are a reduction in daily off time of approximately 1 to 2 hours per day and a reduction in the total levodopa dose of approximately 10 to 30%, achieved without proportionate worsening of overall motor control in patients who tolerate the combined regimen. The agonist provides additional, more continuous dopaminergic receptor stimulation that supplements the pulsatile effect of levodopa, smoothing out wearing-off fluctuations and allowing the levodopa dose to be reduced — thereby also reducing levodopa-related peak-dose complications such as dyskinesias. Extended-release formulations of pramipexole and ropinirole have demonstrated non-inferiority to their immediate-release equivalents in this adjunctive role. Option D is correct.
Option A: Option A is incorrect because off-time reduction of 3 to 4 hours overstates the established clinical benefit, and levodopa dose increase is not required; dopamine agonist addition allows levodopa dose reduction, not escalation.
Option B: Option B is incorrect because complete elimination of off time and complete levodopa withdrawal are not outcomes consistently achieved with agonist adjunct therapy; the realistic clinical benefit is partial off-time reduction and partial levodopa dose-sparing, not elimination of either.
Option C: Option C is incorrect because the 30-minute figure substantially understates the established off-time reduction benefit of agonist addition; approximately 1 to 2 hours per day is the established figure from clinical trials.
Option E: Option E is incorrect because dopamine agonists do not compete with levodopa in a way that reduces levodopa efficacy and requires dose increase; agonists are full or partial agonists at D2 receptors that complement levodopa's effect, and the clinical outcome of agonist addition is levodopa dose reduction, not increase.
16. A patient with Parkinson's disease requires antipsychotic therapy for persistent drug-induced psychosis that has not resolved with dopamine agonist dose reduction. Which of the following correctly identifies all antipsychotic options that are acceptable in Parkinson's disease and the pharmacological basis for their tolerability?
A) Risperidone and quetiapine are the two acceptable antipsychotics in PD; risperidone is preferred because its combined D2 and 5-HT2A antagonism produces a more balanced receptor profile that spares motor function better than quetiapine's histamine-predominant blockade
B) Haloperidol at low doses (0.5 mg or less) is acceptable in PD because at sub-milligram doses striatal D2 occupancy remains below the threshold that causes extrapyramidal effects, making it an option when quetiapine is not available
C) Quetiapine and clozapine are acceptable in PD because of their very low striatal D2 receptor occupancy, which minimizes motor worsening; pimavanserin — a selective 5-HT2A inverse agonist with no D2 receptor activity — is also FDA-approved specifically for Parkinson's disease psychosis and is an additional option that avoids D2 blockade entirely
D) All second-generation (atypical) antipsychotics are acceptable in PD because atypical agents as a class produce clinically insignificant striatal D2 blockade and do not worsen parkinsonism; only first-generation agents are contraindicated
E) Clozapine is the only acceptable antipsychotic in PD; quetiapine has been shown in randomized controlled trials to worsen parkinsonism to a clinically significant degree and is therefore contraindicated, leaving clozapine as the sole option despite its REMS monitoring requirement for agranulocytosis
ANSWER: C
Rationale:
In Parkinson's disease, the acceptable antipsychotic options are defined by their degree of striatal D2 receptor occupancy. Quetiapine has very low affinity for D2 receptors relative to its affinity for histamine H1 and serotonin 5-HT2A receptors, resulting in minimal striatal D2 occupancy at clinical doses and therefore minimal motor worsening in most PD patients. Clozapine has the lowest D2 receptor affinity of any antipsychotic, producing effective antipsychotic activity through non-D2 mechanisms while sparing striatal dopaminergic function; it requires Risk Evaluation and Mitigation Strategy (REMS) monitoring for agranulocytosis. Pimavanserin is a selective 5-HT2A inverse agonist with no affinity for D2, D3, or D4 receptors; it was FDA-approved specifically for hallucinations and delusions associated with Parkinson's disease psychosis and represents a mechanistically distinct option that avoids dopamine receptor blockade entirely. All other antipsychotics — including risperidone, olanzapine, aripiprazole, ziprasidone, and all first-generation agents — produce sufficient striatal D2 blockade to worsen motor function in PD and should be avoided. Option C is correct.
Option A: Option A is incorrect because risperidone is not an acceptable antipsychotic in PD; it produces clinically significant striatal D2 blockade and worsens parkinsonism, making it contraindicated regardless of its 5-HT2A antagonism.
Option B: Option B is incorrect because there is no established sub-milligram haloperidol dose that is safe in PD; haloperidol has the highest D2 receptor affinity of any commonly used antipsychotic, and even sub-milligram doses produce meaningful striatal D2 blockade that worsens motor function in PD patients.
Option D: Option D is incorrect because the claim that all atypical antipsychotics are acceptable in PD is false; agents such as risperidone, olanzapine, and aripiprazole produce clinically significant striatal D2 blockade and should be avoided in PD despite being atypical agents.
Option E: Option E is incorrect because quetiapine is an acceptable option in PD — it is in fact the more commonly used first-choice agent in clinical practice due to its ease of use relative to clozapine; while evidence from small randomized trials has been mixed, quetiapine's low D2 affinity makes it the standard clinical choice ahead of clozapine in most PD patients requiring antipsychotic therapy.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.